Renal Effects of Erythropoietin in Humans

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2013

Study Completion Date

September 30, 2013

Conditions
Renal Effects
Interventions
DRUG

Erythropoietin (Epoetin-beta, NeoRecormon®)

5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.

DRUG

Erythropoietin (Epoetin-beta, NeoRecormon®)

"30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.~On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding."

DRUG

Placebo

1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.

Trial Locations (1)

2100

Department of Clinical Physiology and Nuclear Medicine and PET, Rigshospitalet, Copenhagen

All Listed Sponsors
collaborator

Rigshospitalet, Denmark

OTHER

lead

University of Copenhagen

OTHER

NCT01584921 - Renal Effects of Erythropoietin in Humans | Biotech Hunter | Biotech Hunter